Kasabach-Merritt phenomenon.
The objective of this article is to provide a comprehensive overview of the Kasabach-Merritt Phenomenon. The clinical presentation, laboratory findings, vascular pathology, and pathophysiology are discussed.
Kelly
Michael
M
Department of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplant, Medical College of Wisconsin, Milwaukee, WI 53226, USA. mekelly@mcw.edu
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006390:Hemangioendothelioma / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000175:diagnosis / Q000503:physiopathology; D017713:Platelet Transfusion; D012307:Risk Factors; D013577:Syndrome; D013921:Thrombocytopenia / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology*; D019043:Vascular Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000972:Antineoplastic Agents, Phytogenic